Association of Androgen Receptor, Prostate-Specific Antigen, and CYP19 Gene Polymorphisms with Prostate Carcinoma and Benign Prostatic Hyperplasia in a North Indian Population

被引:13
|
作者
Soni, Abha [1 ]
Bansal, Anju [1 ]
Mishra, Ashwani Kumar [1 ]
Batra, Jyotsna [2 ,3 ]
Singh, Laishram Chandreshwor [1 ]
Chakraborty, Anurupa [1 ]
Yadav, Dhirendra Singh [1 ]
Mohanty, Nayan K. [4 ,5 ]
Saxena, Sunita [1 ]
机构
[1] Natl Inst Pathol ICMR, New Delhi 110029, India
[2] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia
[3] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[4] Safdarjang Hosp, Dept Urol, New Delhi, India
[5] Vardhman Mahavir Med Coll, New Delhi, India
基金
澳大利亚国家健康与医学研究理事会;
关键词
CAG REPEAT LENGTH; CANCER; RISK; AROMATASE; PSA; IDENTIFICATION; EXPRESSION; IMPACT; GGN;
D O I
10.1089/gtmb.2011.0322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The genes involved in androgen pathway and metabolism have been reported to contribute considerably to prostate carcinoma (CaP) risk. The present study investigated the association of androgen receptor (AR), prostate-specific antigen (PSA or KLK3), and cytochrome P450 (CYP19) gene polymorphisms in CaP (n = 105) and benign prostatic hyperplasia (BPH) (n = 120) in comparison to normal healthy controls (n = 106) in an Indian population. We also evaluated the functional consequences of these gene variants on AR and PSA mRNA expression. Significant association of short AR CAG repeats (<= 24) with risk of CaP (odds ratios [OR] = 2.98, p < 0.001) and BPH (OR = 1.96, p = 0.01) was observed; however, CYP19 gene polymorphism was not found to be associated with disease phenotype (p > 0.05). PSA G-158A SNP was found to be significantly associated with risk of CaP (AA: OR = 2.68, p = 0.016 and GA: OR = 2.07, p = 0.018) p-trend 0.031 and BPH (AA: OR = 3.46, p < 0.001 and GA: OR = 2.47, p = 0.03) p-trend 0.009, respectively. PSA G-158A genotype independently increased the risk of developing BPH (OR = 16.37, p < 0.001), irrespective of AR CAG repeat length. Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH. While short AR CAG (<= 24) repeats were associated with higher AR mRNA expression in CaP (p = 0.002), the PSA SNP did not correlate with its mRNA expression. Interestingly, significantly higher risk estimates for CaP were observed for the combined analysis of short AR CAG and CYP19 genotypes (A2A2) (OR = 7.18, p < 0.001) or A2A3 (OR = 7.60, p = 0.004). Our results suggest significant association of androgen signaling gene polymorphisms with risk of CaP and BPH and provide evidence for a putative functional role of AR CAG repeat in regulating its mRNA expression and warrant the need of larger studies in the Indian population to confirm our results.
引用
收藏
页码:835 / 840
页数:6
相关论文
共 50 条
  • [31] INFLUENCE OF TRANSRECTAL HYPERTHERMIA ON PROSTATE-SPECIFIC ANTIGEN IN PROSTATIC-CANCER AND BENIGN PROSTATIC HYPERPLASIA
    STROHMAIER, WL
    FLUCHTER, SH
    WILBERT, DM
    BICHLER, KH
    UROLOGIA INTERNATIONALIS, 1993, 51 (01) : 28 - 31
  • [32] Free/total prostate-specific antigen ratio and prostate composition in men with benign prostatic hyperplasia.
    Pearson, JD
    Landis, PK
    Metter, EJ
    Fozard, JL
    Cadeddu, JA
    Partin, AW
    Epstein, JI
    Carter, HB
    AMERICAN JOURNAL OF HUMAN BIOLOGY, 1997, 9 (01) : 152 - 152
  • [33] Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer
    Hillenbrand, M
    Bastian, M
    Steiner, M
    Zingler, C
    Müller, M
    Wolff, JM
    Seiter, H
    Schuff-Werner, P
    ANTICANCER RESEARCH, 2000, 20 (6D) : 4995 - 4996
  • [34] Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia
    Schaliken, JA
    BJU INTERNATIONAL, 2004, 93 : 5 - 9
  • [35] Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels
    Cramer, SD
    Chang, BL
    Rao, A
    Hawkins, GA
    Zheng, SL
    Wade, WN
    Cooke, RT
    Thomas, LN
    Bleecker, ER
    Catalona, WJ
    Sterling, DA
    Meyers, DA
    Ohar, J
    Xu, JF
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (14): : 1044 - 1053
  • [36] Prostate-Specific Antigen Mass and Free Prostate-Specific Antigen Mass for Predicting the Prostate Volume of Korean Men With Biopsy-Proven Benign Prostatic Hyperplasia
    Park, Tae Yong
    Chae, Ji Yun
    Kim, Jong Wook
    Kim, Jin Wook
    Oh, Mi Mi
    Yoon, Cheol Yong
    Moon, Du Geon
    KOREAN JOURNAL OF UROLOGY, 2013, 54 (09) : 609 - 614
  • [37] Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?
    Mittal, Rama D.
    Mishra, Dhruva K.
    Thangaraj, K.
    Singh, Rajender
    Mandhani, Anil
    STEROIDS, 2007, 72 (04) : 335 - 341
  • [38] Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia
    Kim, Jong Min
    Song, Phil Hyun
    Kim, Hyun Tae
    Moon, Ki Hak
    KOREAN JOURNAL OF UROLOGY, 2011, 52 (06) : 401 - 405
  • [39] ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN AND PROINFLAMMATORY CYTOKINES IN PATHOLOGICAL HUMAN PROSTATE (BENIGN HYPERPLASIA AND CARCINOMA): A STUDY OF TUNISSIAN PATIENTS
    Fraile, B.
    Bouraoui, Y.
    Rodriguez-Berruguete, Gonzalo
    Oueslati, R.
    Paniagua, R.
    Royuela, M.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3283 - 3283
  • [40] PROSTATE-SPECIFIC ANTIGEN VARIATIONS IN MOROCCAN PATIENTS WITH HISTOLOGICALLY PROVEN BENIGN PROSTATIC HYPERPLASIA
    Sadaoui, I.
    Mahfoud, W.
    Joutei, H. A. H.
    Elgnaoui, N.
    Seddiki, A.
    Benomar, H.
    Nadifi, S.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6149 - 6149